(PDF) P082 Circulating Mir-145 as a Marker of Therapeutic

P082 Circulating Mir-145 as a Marker of Therapeutic Response in Patients With Ankylosing Spondylitis Receiving Anti-TNF Therapy

doi 10.1136/annrheumdis-2018-ewrr2018.99

Full Text

Abstract

Available in full text

Date

February 21, 2018

Authors

Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician

Therapeutic Advances in Musculoskeletal Disease

Sports Medicine

English

Recommendations for Starting Anti TNF-α in Patients With Ankylosing Spondylitis

English

A Prospective Clinical Investigation of the Effects of Anti-TNF Alpha Therapy on Exercise Capacity in Patients With Ankylosing Spondylitis

Turkish Journal of Medical Sciences

English

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-Α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients

Archivum Immunologiae et Therapiae Experimentalis

English

Anti TNF-α Therapy Might Be Responsible for an Increased Incidence of Varicocele in Patients With Ankylosing Spondylitis

Turkish Journal of Medical Sciences

English

Response to Anti-TNF-Α Treatment for Secondary Renal Amyloidosis in a Patient With Ankylosing Spondylitis

English

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study

Clinical Genitourinary Cancer

English

First Update of the International ASAS Consensus Statement for the Use of Anti-TNF Agents in Patients With Ankylosing Spondylitis

Annals of the Rheumatic Diseases

Molecular Biology

English

Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors

Frontiers in Medicine

English